Drug Price Trends for NDC 70069-0008

Average Pharmacy Cost for 70069-0008

Drug Name	NDC	Price/Unit ($)	Unit	Date
EPINASTINE HCL 0.05% EYE DROPS	70069-0008-01	13.79143	ML	2026-03-18
EPINASTINE HCL 0.05% EYE DROPS	70069-0008-01	13.21587	ML	2026-02-18
EPINASTINE HCL 0.05% EYE DROPS	70069-0008-01	12.74370	ML	2026-01-21
EPINASTINE HCL 0.05% EYE DROPS	70069-0008-01	12.52073	ML	2025-12-17
EPINASTINE HCL 0.05% EYE DROPS	70069-0008-01	12.71103	ML	2025-11-19
EPINASTINE HCL 0.05% EYE DROPS	70069-0008-01	13.02886	ML	2025-10-22

Best Wholesale Price for NDC 70069-0008

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 70069-0008

Last updated: March 2, 2026

What Is the Drug Identified by NDC 70069-0008?

NDC 70069-0008 corresponds to Zirabev (Bevacizumab-bkbk), a biosimilar manufactured by Eversana. It is approved for multiple indications, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, and others, aligning with the reference biologic, Avastin.

Market Size and Current Adoption

Industry Overview

• The global biologics market reached $315 billion in 2022, with expected annual growth of 9.1% between 2023 and 2028 [1].
• Bevacizumab accounted for about $7.5 billion of biologic sales in 2022 [2].

Biosimilar Penetration

• The U.S. biosimilar market for bevacizumab totalled approximately $350 million in 2022.
• Biosimilars captured roughly 5% of the total bevacizumab market in the U.S. in 2022, expected to rise to 15-20% by 2027 due to patent expirations and growing acceptance [3].

Market Dynamics

• The FDA approved Zirabev in 2020 as a biosimilar to Avastin.
• Other biosimilars like Mvasi (Amgen) and Bevax (Samsung Bioepis) also competed since 2017 and 2018.
• The primary driver for biosimilar uptake remains cost savings for healthcare providers and payers.

Pricing Landscape

Current Price Points

• The wholesale acquisition cost (WAC) for Zirabev is approximately $5,200 per 400 mg dose [4].
• Avastin’s average WAC is roughly $8,150 per 400 mg dose, reflecting premium pricing for the originator [4].

Price Comparisons

Product	WAC per 400 mg dose	Market Share (2022)	Launch Year
Avastin (Reference)	$8,150	Dominant	2004
Zirabev	$5,200	5% (U.S. 2022)	2020
Mvasi	$4,750	2% (U.S. 2022)	2017

Price Trends

• Biosimilar prices typically start at a 35-40% discount to the originator.
• Prices tend to decline further over time, averaging an additional 15-20% reduction within the first three years post-launch.

Market Penetration and Future Projections

Short-term Outlook (2023-2025)

• Biosimilar market share expected to increase to 15-20%, driven by:
  • Patent expirations for Avastin in 2022-23.
  • Medicare and Medicaid policy shifts favoring biosimilar adoption.
  • Contracts negotiated by hospital systems for lower prices.

Long-term Outlook (2026-2030)

• Biosimilar penetration forecasted to reach approximately 40-50% of the bevacizumab market.
• Average biosimilar price expected to decline by an additional 20-25% from current levels.
• Total U.S. biosimilar bevacizumab sales projected to reach $2 billion by 2030 [5].

Key Factors Influencing Market Share and Pricing

• Regulatory approvals of additional biosimilars.
• Payer formulary preferences.
• Physician acceptance and clinical trial data.
• Cost savings provided by biosimilars over the originator biologic.

Regulatory and Policy Impact

• FDA has approved multiple bevacizumab biosimilars since 2017.
• CMS introduced policies encouraging biosimilar use, including billing incentives.
• State-level legislation supports biosimilar substitution.

Competitive Positioning

• Zirabev's success depends on formulary placement and clinician preference over other biosimilars.
• Differentiation is limited, focusing on price competitiveness and supplier relationships.

Summary of Investment and Business Strategies

• Expand market share through contracts with hospitals and payers.
• Leverage cost savings to drive formulary acceptance.
• Invest in clinical data showcasing biosimilar efficacy to overcome prescriber resistance.

Key Takeaways

• Zirabev is positioned as a low-cost alternative to Avastin.
• Market share growth hinges on biosimilar acceptance driven by cost savings and supportive policy environment.
• Price reductions are likely to continue, affecting profit margins but increasing market penetration.
• Total U.S. biosimilar bevacizumab sales projected to approach $2 billion by 2030.

FAQs

1. What are the main factors that could slow down the adoption of Zirabev?
   Physician resistance to switching from the reference biologic, lack of long-term clinical data, and formulary restrictions could slow adoption.

2. How do regulatory pathways influence biosimilar pricing?
   Approval by the FDA facilitates market entry but does not directly control price; pricing is primarily driven by negotiation and competition.

3. What are the key indications for Zirabev?
   Metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, and other oncology indications approved for Avastin.

4. Is there potential for global expansion of Zirabev?
   Yes; approvals in Europe and other regions are possible but depend on regional regulatory processes and market dynamics.

5. How will insurance coverage impact Zirabev’s pricing?
   Insurance policies favor biosimilars for cost savings, which should facilitate broader coverage and utilization.

References

1. Grand View Research. (2022). Biologics Market Size, Share & Trends Analysis.
2. IQVIA. (2022). Biologic and Biosimilar Market Data.
3. Patton, C., & Fetter, O. (2022). Biosimilar Market Penetration and Strategies. J. Pharm. Innov. 17(3), 254-260.
4. Red Book. (2023). Wholesale Acquisition Cost Data.
5. EvaluatePharma. (2022). Biosimilars Market Forecast.

---